Personal information
Biography
For 35+ years, Dr. Yarasheski's passion to conduct translational clinical research has focused on using various forms of chromatography-mass spectrometry to characterize and quantify biomolecules present in human biofluids and tissues, and that reveal underlying alterations in protein and amino acid metabolism that contribute to the pathogenesis of several conditions: unsuccessful aging, neurodegenerative disorders, infectious diseases, and cardiometabolic complications. For 29 of those years, Dr. Yarasheski was employed in the Department of Internal Medicine at Washington University School of Medicine where he rose to the rank of Full Professor, co-Directed the Biomedical Mass Spectrometry Research Facility, fully supported his independent mass spectrometry-based clinical research program, and collaborated with many investigators, institutions, and Foundations around the globe on their patient-oriented projects that required mass spectrometry analysis. In 2016, Dr. Yarasheski joined C2N Diagnostics as Senior Vice President where he directs and oversees all laboratory personnel and mass spectrometry research and discovery efforts focused on developing and validating fluid biomarkers for neurodegeneration and AD pathology. C2N Diagnostics' first commercially available mass spectrometry-based plasma diagnostic test for brain amyloid pathology was released in 2020; www.PrecivityAD.com.
Activities
Employment (6)
Education and qualifications (1)
Funding (8)
Works (50 of 276)
10.1016/j.jnutbio.2012.03.021
10.1055/s-0032-1327659